Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Nov 17, 2021

Atea Announces Update on Collaboration with Roche for AT-527

TOKYO, November 17, 2021 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Atea issued a press release on its collaboration with Roche for the investigational oral COVID-19 treatment AT-527.

Please refer to the link below for details:
Atea Pharmaceuticals Provides Update on Strategic Collaboration with Roche
https://ir.ateapharma.com/news-releases/news-release-details/atea-pharmaceuticals-provides-update-strategic-collaboration

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Takayuki Sakurai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top